Dana-Farber Cancer Institute | Strategic Alliance Partners

March 09, 2024

Ko Un “Clara” Park, MD, discusses the FDA's vote in support of Lumisight for patients with breast cancer undergoing breast conserving surgery.

March 06, 2024

Hana Safah, MD, reviews the NIH staging system for graft-vs-host disease and discusses the importance of staging in determining prognosis and informing treatment decisions.

March 06, 2024

Corey Cutler, MD, MPH, discusses the role of prognostic markers in graft-vs-host disease and how they can potentially inform treatment selection.

March 05, 2024

Different immunomodulatory mechanisms are at work depending on the type of treatment and the genetic makeup of the cancer in RCC.

February 29, 2024

The panel provides advice for community providers treating patients with chronic GVHD, stressing effective communication, staying updated on evolving drugs, and collaborating with specialized multidisciplinary groups for optimal patient care.

February 29, 2024

The expert doctors discuss the impact of chronic GVHD on long-term survivors' quality of life (QoL). The panel explores the significance of patient-reported outcomes (PROs), challenges in their implementation, and the evolving role of PROs in assessing and improving QoL in chronic GVHD patients.

February 28, 2024

Hematologist-oncologists Corey Cutler, MD, MPH, and Hana Safah, MD, discuss how graft-vs-host disease presents and the importance of early intervention.

February 28, 2024

Experts on graft-vs-host disease (GvHD) introduce themselves and provide an overview of GvHD, highlighting diagnosis, symptoms, risk stratification, and prevention.

February 28, 2024

Pasi A. Jänne, MD, PhD discusses the FDA approval of osimertinib plus chemotherapy for patients with EGFR-positive non–small cell lung cancer.

February 26, 2024

In case you missed it, read a recap of every episode of OncLive On Air recorded in January 2024.

February 22, 2024

Drs Yi-Bin Chen, Corey Cutler, Hannah Choe, and Mitchell Horwitz share their predictions for the next 3 to 5 years in chronic GVHD management. The panel anticipates advancements in earlier treatment, potential elimination of frontline corticosteroids, and a shift towards preventive strategies and personalized medicine.

February 22, 2024

The panel reviews axatilimab, an emerging agent for chronic GVHD under clinical studies. The experts explore findings from the Agave-201 study, highlighting potential challenges of intravenous administration and axatilimab’s unique mechanisms.

February 20, 2024

A panel of experts discuss future directions and remaining unmet needs for patients with relapsed/refractory MCL.

February 19, 2024

Sarah Sammons, MD, discusses research efforts in breast cancer focused on HER2-directed therapeutic approaches with central nervous system activity.

February 19, 2024

Catherine J. Wu, MD, of Dana-Farber Cancer Institute, has been awarded the Sjöberg Prize today for her pioneering research in the field of personalized vaccines to treat cancer.

February 16, 2024

Pasi A. Jänne, MD, PhD, discusses the FDA approval of osimertinib plus chemotherapy in patients with EGFR-mutant locally advanced or metastatic NSCLC.

February 15, 2024

Sarah Sammons, MD, discusses what is known about the incidence of brain metastases in patients with breast cancer.

February 15, 2024

Drs Yi-Bin Chen, Corey Cutler, Hannah Choe, and Mitchell Horwitz discuss a complex chronic GVHD case post-allogeneic transplant. The panel explores third-line options, including belumosudil, ibrutinib, photopheresis, and clinical trials, emphasizing shared decision-making and the need for well-designed trials in guiding treatment decisions.

February 15, 2024

Drs Yi-Bin Chen, Corey Cutler, Hannah Choe, and Mitchell Horwitz review a clinical scenario of chronic GVHD post-allogeneic transplant. They explore treatment options and emphasize shared decision-making, considering patient preferences and therapeutic benefits.

February 14, 2024

In the treatment of unresectable or metastatic Merkel cell carcinoma, immune checkpoint inhibitors have activity and tolerability.